Substituted pyrazoles as p38 kinase inhibitors

US6423713B1 · kind B1 · utility

Assignee

• G.D. Searle LLC · US

Inventors

• Ashok Anantanarayan · Hainesville, US
• Michael Clare · Skokie, US
• Paul W. Collins · Deerfield, US
• Joyce Z. Crich · Glenview, US
• Rajesh Devraj · Chesterfield, US
• Daniel L. Flynn · Lawrence, US
• Lifeng Geng · Skokie, US
• Matthew J. Graneto · Chesterfield, US
• Cathleen Hanau · Chesterfield, US
• Gunnar J. Hanson · Cambridge, US
• Susan J. Hartmann · Kirkwood, US
• Michael Hepperle · Boston, US
• He Huang · Northbrook, US
• Francis J. Koszyk · Prospect Heights, US
• Shuyuan Liao · Northbrook, US
• Suzanne Metz · Chesterfield, US
• Richard A. Partis · Evanston, US
• Thao Perry · San Jose, US
• Shashidhar N. Rao · Chesterfield, US
• Shaun Raj Selness · Chesterfield, US
• Michael S. South · Chesterfield, US
• Michael A. Stealey · Libertyville, US
• John J. Talley · Chesterfield, US
• Michael L. Vazquez · Saint Louis, US
• Richard M. Weier · Lake Bluff, US
• Xiangdong Xi · Evanston, US
• Ish Khanna · Vernon Hills, US
• Yi Yu · Skokie, US

Key dates

• Filing date: Jul 31, 2001
• Grant date: Jul 23, 2002
• Expiry date: Jul 31, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA wherein R1, R2, R3 and R4 are as described in the specification.